Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PROTACs: great opportunities for academia and industry
Xiuyun Sun, Hongying Gao, Yiqing Yang, et al.
Signal Transduction and Targeted Therapy (2019) Vol. 4, Iss. 1
Open Access | Times Cited: 513

Showing 1-25 of 513 citing articles:

Advancing targeted protein degradation for cancer therapy
Brandon Dale, Meng Cheng, Kwang‐Su Park, et al.
Nature reviews. Cancer (2021) Vol. 21, Iss. 10, pp. 638-654
Open Access | Times Cited: 433
PROTACs: past, present and future
Ke Li, Craig M. Crews
Chemical Society Reviews (2022) Vol. 51, Iss. 12, pp. 5214-5236
Open Access | Times Cited: 419
Targeted protein degradation: mechanisms, strategies and application
Lin Zhao, Jia Zhao, Kunhong Zhong, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 415
Current strategies for the design of PROTAC linkers: a critical review
Robert I. Troup, Charlene Fallan, Matthias G. J. Baud
Exploration of Targeted Anti-tumor Therapy (2020) Vol. 1, Iss. 5
Open Access | Times Cited: 251
PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
Simin Qi, Jinyun Dong, Zhiyuan Xu, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 205
Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs
Shanique Alabi, Craig M. Crews
Journal of Biological Chemistry (2021) Vol. 296, pp. 100647-100647
Open Access | Times Cited: 189
Protein arginine methyltransferases: promising targets for cancer therapy
Jee Won Hwang, Yena Cho, Gyu‐Un Bae, et al.
Experimental & Molecular Medicine (2021) Vol. 53, Iss. 5, pp. 788-808
Open Access | Times Cited: 182
The PROTACtable genome
Melanie Schneider, Chris J. Radoux, Andrew Hercules, et al.
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 10, pp. 789-797
Closed Access | Times Cited: 172
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
Ming He, Chao-Guo Cao, Zhihao Ni, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 168
Chemistries of bifunctional PROTAC degraders
Chao-Guo Cao, Ming He, Liguo Wang, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 16, pp. 7066-7114
Closed Access | Times Cited: 168
Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges
Shenxin Zeng, Wenhai Huang, Xiaoliang Zheng, et al.
European Journal of Medicinal Chemistry (2020) Vol. 210, pp. 112981-112981
Closed Access | Times Cited: 165
Understudied proteins: opportunities and challenges for functional proteomics
Georg Kustatscher, Tom Collins, Anne‐Claude Gingras, et al.
Nature Methods (2022) Vol. 19, Iss. 7, pp. 774-779
Open Access | Times Cited: 161
E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points
Aleša Bricelj, Christian Steinebach, Robert D. Kuchta, et al.
Frontiers in Chemistry (2021) Vol. 9
Open Access | Times Cited: 158
Recent Developments in PROTAC‐Mediated Protein Degradation: From Bench to Clinic
Zhenyi Hu, Craig M. Crews
ChemBioChem (2021) Vol. 23, Iss. 2
Open Access | Times Cited: 158
Alternative approaches to target Myc for cancer treatment
Chen Wang, Jiawei Zhang, Jie Yin, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 154
Unraveling the Role of Linker Design in Proteolysis Targeting Chimeras
Troy A. Bemis, James J. La Clair, Michael D. Burkart
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 12, pp. 8042-8052
Closed Access | Times Cited: 152
The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020
Yuzhi Liu, Chengyuan Liang, Liang Xin, et al.
European Journal of Medicinal Chemistry (2020) Vol. 206, pp. 112711-112711
Open Access | Times Cited: 151
Emerging New Concepts of Degrader Technologies
Yu Ding, Yiyan Fei, Boxun Lu
Trends in Pharmacological Sciences (2020) Vol. 41, Iss. 7, pp. 464-474
Open Access | Times Cited: 146
Cancer epigenetics in clinical practice
Verónica Dávalos, Manel Esteller
CA A Cancer Journal for Clinicians (2022) Vol. 73, Iss. 4, pp. 376-424
Open Access | Times Cited: 146
A unified model for the G1/S cell cycle transition
Samuel Hume, Grigory L. Dianov, Kristijan Ramadan
Nucleic Acids Research (2020) Vol. 48, Iss. 22, pp. 12483-12501
Open Access | Times Cited: 144
Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends
Kunal Nepali, Jing‐Ping Liou
Journal of Biomedical Science (2021) Vol. 28, Iss. 1
Open Access | Times Cited: 143
Bifunctional small molecules that mediate the degradation of extracellular proteins
David Caianiello, Mengwen Zhang, Jason D. Ray, et al.
Nature Chemical Biology (2021) Vol. 17, Iss. 9, pp. 947-953
Closed Access | Times Cited: 142
A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo
Christiane Kofink, Nicole Trainor, Barbara Mair, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 141
Targeted degradation of transcription factors by TRAFTACs: TRAnscription Factor TArgeting Chimeras
Kusal T. G. Samarasinghe, Saul Jaime‐Figueroa, Michael Burgess, et al.
Cell chemical biology (2021) Vol. 28, Iss. 5, pp. 648-661.e5
Open Access | Times Cited: 133
From Conception to Development: Investigating PROTACs Features for Improved Cell Permeability and Successful Protein Degradation
Carlotta Cecchini, Sara Pannilunghi, Sébastien Tardy, et al.
Frontiers in Chemistry (2021) Vol. 9
Open Access | Times Cited: 123
Page 1 - Next Page

Scroll to top